A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.

Yiming Cheng,Ying Ye,Allison Gaudy,Atalanta Ghosh,Yongjun Xue, Alice Wang,Simon Zhou,Yan Li

Clinical pharmacology : advances and applications（2023）

引用 0|浏览10

暂无评分

摘要

In summary, 1 mg single oral dose of iberdomide was generally well-tolerated. HI (mild, moderate or severe) had no clinically relevant impact on iberdomide PK and therefore, no dose adjustment is warranted.

查看译文

关键词

hepatic impairment,iberdomide,pharmacokinetics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要